Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

  • Motas, Sandra|||0000-0003-2748-5952
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Garcia, Miquel|||0000-0002-1602-4993
  • Marcó, Sara|||0000-0003-3502-5198
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Molas, Maria
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Maggioni, Luca
  • León, Xavier|||0000-0002-8393-2721
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease characterized by severe neurologic and somatic disease caused by deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes the glycosaminoglycans heparan and dermatan sulphate. Intravenous enzyme replacement therapy (ERT) currently constitutes the only approved therapeutic option for MPSII. However, the inability of recombinant IDS to efficiently cross the blood-brain barrier (BBB) limits ERT efficacy in treating neurological symptoms. Here, we report a gene therapy approach for MPSII through direct delivery of vectors to the CNS. Through a minimally invasive procedure, we administered adeno-associated virus vectors encoding IDS (AAV9-Ids) to the cerebrospinal fluid of MPSII mice with already established disease. Treated mice showed a significant increase in IDS activity throughout the encephalon, with full resolution of lysosomal storage lesions, reversal of lysosomal dysfunction, normalization of brain transcriptomic signature, and disappearance of neuroinflammation. Moreover, our vector also transduced the liver, providing a peripheral source of therapeutic protein that corrected storage pathology in visceral organs, with evidence of cross-correction of nontransduced organs by circulating enzyme. Importantly, AAV9-Ids-treated MPSII mice showed normalization of behavioral deficits and considerably prolonged survival. These results provide a strong proof of concept for the clinical translation of our approach for the treatment of Hunter syndrome patients with cognitive impairment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

In Vivo Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment Horizon

  • Marcó, Sara|||0000-0003-3502-5198
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
For most lysosomal storage diseases (LSDs), there is no cure. Gene therapy is an attractive tool for treatment of LSDs caused by deficiencies in secretable lysosomal enzymes, in which neither full restoration of normal enzymatic activity nor transduction of all cells of the affected organ is necessary. However, some LSDs, such as mucopolysaccharidosis type III (MPSIII) diseases or Sanfilippo syndrome, represent a difficult challenge because patients suffer severe neurodegeneration with mild somatic alterations. The disease's main target is the central nervous system (CNS) and enzymes do not efficiently cross the blood-brain barrier (BBB) even if present at very high concentration in circulation. No specific treatment has been approved for MPSIII. In this study, we discuss the adeno-associated virus (AAV) vector-mediated gene transfer strategies currently being developed for MPSIII disease. These strategies rely on local delivery of AAV vectors to the CNS either through direct intraparenchymal injection at several sites or through delivery to the cerebrospinal fluid (CSF), which bathes the whole CNS, or exploit the properties of certain AAV serotypes capable of crossing the BBB upon systemic administration. Although studies in small and large animal models of MPSIII diseases have provided evidence supporting the efficacy and safety of all these strategies, there are considerable differences between the different routes of administration in terms of procedure-associated risks, vector dose requirements, sensitivity to the effect of circulating neutralizing antibodies that block AAV transduction, and potential toxicity. Ongoing clinical studies should shed light on which gene transfer strategy leads to highest clinical benefits while minimizing risks. The development of all these strategies opens a new horizon for treatment of not only MPSIII and other LSDs but also of a wide range of neurological diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC

  • Marcó, Sara|||0000-0003-3502-5198
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Motas, Sandra|||0000-0003-2748-5952
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Garcia, Miquel|||0000-0002-1602-4993
  • Molas, Maria
  • Villacampa, Pilar|||0000-0002-2860-7475
  • Melia, Cristian S.
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis type IIIC (MPSIIIC) is a severe lysosomal storage disease caused by deficiency in activity of the transmembrane enzyme heparan-α-glucosaminide N-acetyltransferase (HGSNAT) that catalyses the N-acetylation of α-glucosamine residues of heparan sulfate. Enzyme deficiency causes abnormal substrate accumulation in lysosomes, leading to progressive and severe neurodegeneration, somatic pathology and early death. There is no cure for MPSIIIC, and development of new therapies is challenging because of the unfeasibility of cross-correction. In this study, we generated a new mouse model of MPSIIIC by targeted disruption of the Hgsnat gene. Successful targeting left LacZ expression under control of the Hgsnat promoter, allowing investigation into sites of endogenous expression, which was particularly prominent in the CNS, but was also detectable in peripheral organs. Signs of CNS storage pathology, including glycosaminoglycan accumulation, lysosomal distension, lysosomal dysfunction and neuroinflammation were detected in 2-month-old animals and progressed with age. Glycosaminoglycan accumulation and ultrastructural changes were also observed in most somatic organs, but lysosomal pathology seemed most severe in liver. Furthermore, HGSNAT-deficient mice had altered locomotor and exploratory activity and shortened lifespan. Hence, this animal model recapitulates human MPSIIIC and provides a useful tool for the study of disease physiopathology and the development of new therapeutic approaches. Summary: A new animal model of the severe neurodegenerative lysosomal disorder mucopolysaccharidosis IIIC recapitulates the human disease, with progressive CNS and somatic lysosomal pathology, and shortened lifespan.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal

  • Marcó, Sara|||0000-0003-3502-5198
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Molas, Maria
  • Garcia, Miquel|||0000-0002-1602-4993
  • León, Xavier|||0000-0002-8393-2721
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Pérez, Jennifer
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Carretero i Romay, Ana|||0000-0001-9377-4926
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Andaluz Martínez, Anna|||0000-0001-8097-8110
  • Espada, Yvonne|||0000-0003-1556-6587
  • Añor Torres, Sònia|||0000-0002-1099-7698
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Delivery of adeno-associated viral vectors (AAVs) to cerebrospinal fluid (CSF) has emerged as a promising approach to achieve widespread transduction of the central nervous system (CNS) and peripheral nervous system (PNS), with direct applicability to the treatment of a wide range of neurological diseases, particularly lysosomal storage diseases. Although studies in small animal models have provided proof of concept and experiments in large animals demonstrated feasibility in bigger brains, there is not much information on long-term safety or durability of the effect. Here, we report a 7-year study in healthy beagle dogs after intra-CSF delivery of a single, clinically relevant dose (2 × 10 13 vg/dog) of AAV9 vectors carrying the canine sulfamidase, the enzyme deficient in mucopolysaccharidosis type IIIA. Periodic monitoring of CSF and blood, clinical and neurological evaluations, and magnetic resonance and ultrasound imaging of target organs demonstrated no toxicity related to treatment. AAV9-mediated gene transfer resulted in detection of sulfamidase activity in CSF throughout the study. Analysis at tissue level showed widespread sulfamidase expression and activity in the absence of histological findings in any region of encephalon, spinal cord, or dorsal root ganglia. Altogether, these results provide proof of durability of expression and long-term safety for intra-CSF delivery of AAV-based gene transfer vectors encoding therapeutic proteins to the CNS. Seven-year follow-up of dogs after intra-CSF administration of AAV9-sulfamidase vectors results in detection of sulfamidase activity in CSF and widespread transgene expression in CNS, PNS, and liver, in the absence of any adverse events. Proof of durability and safety of this gene therapy support its clinical translation to treat CNS diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biochemical, histological and functional correction of mucopolysaccharidosis Type IIIB by intra-cerebrospinal fluid gene therapy

  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Garcia, Miquel|||0000-0002-1602-4993
  • Marcó, Sara|||0000-0003-3502-5198
  • Motas, Sandra|||0000-0003-2748-5952
  • Villacampa, Pilar|||0000-0002-2860-7475
  • Maggioni, Luca
  • León, Xavier|||0000-0002-8393-2721
  • Molas Laplana, Maria|||0000-0002-3215-515X
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Leborgne, Christian
  • Moll, Xavier|||0000-0002-2992-9361
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Mingozzi, Federico
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Añor Torres, Sònia|||0000-0002-1099-7698
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Gene therapy is an attractive tool for the treatment of monogenic disorders, in particular for lysosomal storage diseases (LSD) caused by deficiencies in secretable lysosomal enzymes in which neither full restoration of normal enzymatic activity nor transduction of all affected cells are necessary. However, some LSD such as Mucopolysaccharidosis Type IIIB (MPSIIIB) are challenging because the disease's main target organ is the brain and enzymes do not efficiently cross the blood-brain barrier even if present at very high concentration in circulation. To overcome these limitations,we delivered AAV9 vectors encoding for α-N-acetylglucosaminidase (NAGLU) to the Cerebrospinal Fluid (CSF) of MPSIIIB mice with the disease already detectable at biochemical, histological and functional level. Restoration of enzymatic activity in Central Nervous System (CNS) resulted in normalization of glycosaminoglycan content and lysosomal physiology, resolved neuroinflammation and restored the pattern of gene expression in brain similar to that of healthy animals. Additionally, transduction of the liver due to passage of vectors to the circulation led to whole-body disease correction. Treated animals also showed reversal of behavioural deficits and extended lifespan. Importantly, when the levels of enzymatic activity were monitored in the CSF of dogs following administration of canine NAGLU-coding vectors to animals that were either naïve or had pre-existing immunity against AAV9, similar levels of activity were achieved, suggesting that CNS efficacy would not be compromised in patients seropositive for AAV9. Our studies provide a strong rationale for the clinical development of this novel therapeutic approach as the treatment for MPSIIIB.